open access

Vol 24, No 1 (2017)
Original articles — Clinical cardiology
Published online: 2016-10-11
Get Citation

Impact of cyclosporine A use in the prevention of reperfusion injury in acute myocardial infarction: A meta-analysis

Sunil Upadhaya, Seetharamprasad Madala, Ramkaji Baniya, Suresh Kumar Subedi, Kalyan Saginala, Ghassan Bachuwa
DOI: 10.5603/CJ.a2016.0091
·
Pubmed: 27734457
·
Cardiol J 2017;24(1):43-50.

open access

Vol 24, No 1 (2017)
Original articles — Clinical cardiology
Published online: 2016-10-11

Abstract

Background: Reperfusion injury is an important limiting factor associated with revascularization in acute myocardial infarction (AMI). Various therapies have been tried in an attempt to prevent reperfusion injury, but the search has been elusive. The role of cyclosporine A (CsA) in the prevention of reperfusion injury in AMI is still not clear. The objective of this study was to find out whether CsA is beneficial in reducing reperfusion injury in acute ST elevation myocardial infarction.

Methods: We performed a systematic search of Pubmed, Scopus, clinicaltrial.gov, and Cochrane Database for randomized control trials (RCT) measuring the effect of CsA in AMI compared to a placebo. The Mantel-Haenszel method and random effect model were used to analyze the data. A total of 1,566 patients (776 in the CsA group and 790 in the placebo group), who participated in 5 RCTs were included in our meta-analysis.

Results: We did not find any significant differences between the CsA and placebo groups in terms of all-cause death (odds ratio [OR] 1.21, 95% confidence interval [CI] 0.78–1.87) and cardiovascular death (OR 1.05, 95% CI 0.66–2.49). Similarly, we did not find any significant differences in terms of cardiogenic shock, recurrent ischemia and myocardial infarction, heart failure and echocardiographic outcomes.

Conclusions: Cyclosporine A is not helpful in preventing reperfusion injury in AMI.  

Abstract

Background: Reperfusion injury is an important limiting factor associated with revascularization in acute myocardial infarction (AMI). Various therapies have been tried in an attempt to prevent reperfusion injury, but the search has been elusive. The role of cyclosporine A (CsA) in the prevention of reperfusion injury in AMI is still not clear. The objective of this study was to find out whether CsA is beneficial in reducing reperfusion injury in acute ST elevation myocardial infarction.

Methods: We performed a systematic search of Pubmed, Scopus, clinicaltrial.gov, and Cochrane Database for randomized control trials (RCT) measuring the effect of CsA in AMI compared to a placebo. The Mantel-Haenszel method and random effect model were used to analyze the data. A total of 1,566 patients (776 in the CsA group and 790 in the placebo group), who participated in 5 RCTs were included in our meta-analysis.

Results: We did not find any significant differences between the CsA and placebo groups in terms of all-cause death (odds ratio [OR] 1.21, 95% confidence interval [CI] 0.78–1.87) and cardiovascular death (OR 1.05, 95% CI 0.66–2.49). Similarly, we did not find any significant differences in terms of cardiogenic shock, recurrent ischemia and myocardial infarction, heart failure and echocardiographic outcomes.

Conclusions: Cyclosporine A is not helpful in preventing reperfusion injury in AMI.  

Get Citation

Keywords

myocardial infarction, reperfusion injury, cyclosporine A, mitochondrial permeability transition pore protein

About this article
Title

Impact of cyclosporine A use in the prevention of reperfusion injury in acute myocardial infarction: A meta-analysis

Journal

Cardiology Journal

Issue

Vol 24, No 1 (2017)

Pages

43-50

Published online

2016-10-11

DOI

10.5603/CJ.a2016.0091

Pubmed

27734457

Bibliographic record

Cardiol J 2017;24(1):43-50.

Keywords

myocardial infarction
reperfusion injury
cyclosporine A
mitochondrial permeability transition pore protein

Authors

Sunil Upadhaya
Seetharamprasad Madala
Ramkaji Baniya
Suresh Kumar Subedi
Kalyan Saginala
Ghassan Bachuwa

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl